Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
Sonoma Pharmaceuticals Inc
Long-Term Debt
Sonoma Pharmaceuticals Inc
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Long-Term Debt
$25.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Long-Term Debt
$49.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
54%
|
CAGR 10-Years
21%
|
|
Pfizer Inc
NYSE:PFE
|
Long-Term Debt
$61.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
Merck & Co Inc
NYSE:MRK
|
Long-Term Debt
$31.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Long-Term Debt
$24.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
See Also
What is Sonoma Pharmaceuticals Inc's Long-Term Debt?
Long-Term Debt
0
USD
Based on the financial report for Dec 31, 2023, Sonoma Pharmaceuticals Inc's Long-Term Debt amounts to 0 USD.